Lee's Pharmaceutical Holdings Ltd. engages in the development, manufacture, and sale of pharmaceutical products. The company employs 1,036 full-time employees The company went IPO on 2002-07-15. The firm operates its business through two segments. The Imported Products segment is engaged in the sale of imported products. Its imported products include Keyan injection, Fipril oral solution and others. The Proprietary Products segment is engaged in the manufacture and sale of self-developed products. Its R&D products include Resilicon Tablets, ADASUVE Inhalation Powder and others. The firm's medicines cover the fields of cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology. The firm mainly operates its business in mainland China, Hong Kong and Taiwan.
00950.HK stock price ended at $1.63 on 金曜日, after rising 0.62%
On the latest trading day Jan 16, 2026, the stock price of 00950.HK rose by 0.62%, climbing from $1.62 to $1.63. Throughout the session, the stock experienced a volatility of 3.11%, with prices fluctuating between a daily low of $1.61 and a high of $1.66. Alongside this price increase, trading volume also rose by 403.0K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 604.0K shares were traded, amounting to a market value of approximately $959.8M.